Literature DB >> 23401451

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Kadoaki Ohashi1, Yosef E Maruvka, Franziska Michor, William Pao.   

Abstract

PURPOSE: EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease.
METHODS: This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.
RESULTS: The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.
CONCLUSION: The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23401451      PMCID: PMC3589701          DOI: 10.1200/JCO.2012.43.3912

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  100 in total

1.  Chipping away at the lung cancer genome.

Authors:  William Pao; Katherine E Hutchinson
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

2.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.

Authors:  Mai He; Marzia Capelletti; Khedoudja Nafa; Cai-Hong Yun; Maria E Arcila; Vincent A Miller; Michelle S Ginsberg; Binsheng Zhao; Mark G Kris; Michael J Eck; Pasi A Jänne; Marc Ladanyi; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2011-12-21       Impact factor: 12.531

5.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.

Authors:  Tatsuya Katayama; Junichi Shimizu; Kenichi Suda; Ryoichi Onozato; Takayuki Fukui; Simon Ito; Shunzo Hatooka; Taijiro Sueda; Toyoaki Hida; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

7.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 8.  Tobacco control in the United States--recent progress and opportunities.

Authors:  Vilma Cokkinides; Priti Bandi; Catherine McMahon; Ahmedin Jemal; Thomas Glynn; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2009 Nov-Dec       Impact factor: 508.702

9.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

10.  Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Authors:  Jin Soo Lee; Vera Hirsh; Keunchil Park; Shukui Qin; Cesar R Blajman; Reury-Perng Perng; Yuh-Min Chen; Laura Emerson; Peter Langmuir; Christian Manegold
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

View more
  198 in total

1.  A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.

Authors:  Anja Bastian; Jessica E Thorpe; Bryan C Disch; Lora C Bailey-Downs; Aleem Gangjee; Ravi K V Devambatla; Jim Henthorn; Kenneth M Humphries; Shraddha S Vadvalkar; Michael A Ihnat
Journal:  J Pharmacol Exp Ther       Date:  2015-02-26       Impact factor: 4.030

Review 2.  New treatment options for lung adenocarcinoma--in view of molecular background.

Authors:  Nora Bittner; Gyula Ostoros; Lajos Géczi
Journal:  Pathol Oncol Res       Date:  2013-12-05       Impact factor: 3.201

Review 3.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 4.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

5.  The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.

Authors:  Simone de Leon Martini; Carolina Beatriz Müller; Rosalva Thereza Meurer; Marilda da Cruz Fernandes; Rodrigo Mariano; Mariel Barbachan E Silva; Fábio Klamt; Cristiano Feijó Andrade
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

6.  Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Authors:  Jihye Kim; Vihas T Vasu; Rangnath Mishra; Katherine R Singleton; Minjae Yoo; Sonia M Leach; Eveline Farias-Hesson; Robert J Mason; Jaewoo Kang; Preveen Ramamoorthy; Jeffrey A Kern; Lynn E Heasley; James H Finigan; Aik Choon Tan
Journal:  Bioinformatics       Date:  2014-05-07       Impact factor: 6.937

7.  Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Authors:  Valentina Pirazzoli; Caroline Nebhan; Xiaoling Song; Anna Wurtz; Zenta Walther; Guoping Cai; Zhongming Zhao; Peilin Jia; Elisa de Stanchina; Erik M Shapiro; Molly Gale; Ruonan Yin; Leora Horn; David P Carbone; Philip J Stephens; Vincent Miller; Scott Gettinger; William Pao; Katerina Politi
Journal:  Cell Rep       Date:  2014-05-09       Impact factor: 9.423

8.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.

Authors:  Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

9.  Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Authors:  Shigeru Kawabata; José R Mercado-Matos; M Christine Hollander; Danielle Donahue; Willie Wilson; Lucia Regales; Mohit Butaney; William Pao; Kwok-Kin Wong; Pasi A Jänne; Phillip A Dennis
Journal:  Cell Rep       Date:  2014-06-12       Impact factor: 9.423

10.  Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.

Authors:  Margaret Soucheray; Marzia Capelletti; Inés Pulido; Yanan Kuang; Cloud P Paweletz; Jeffrey H Becker; Eiki Kikuchi; Chunxiao Xu; Tarun B Patel; Fatima Al-Shahrour; Julián Carretero; Kwok-Kin Wong; Pasi A Jänne; Geoffrey I Shapiro; Takeshi Shimamura
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.